Literature DB >> 8717384

Particle-mediated nucleic acid immunization.

J R Haynes1, D E McCabe, W F Swain, G Widera, J T Fuller.   

Abstract

Nucleic acid immunization involves the direct in vivo administration of antigen-encoding plasmid DNA molecules that results in the de novo production of correctly folded microbial antigens at the site of DNA delivery. While this process can lead to the development of neutralizing antibody responses recognizing authentic protein conformations, in vivo antigen production also results in epitope presentation via the MHC class I antigen processing pathway, leading to the elicitation of cytotoxic cellular immune responses. Recent efforts in the authors' laboratories have focused on use of the Accell gene delivery system (gene gun) to achieve the direct, intracellular delivery of small quantities of DNA into cells of the epidermis. The gene gun approach to nucleic acid vaccination capitalizes on the synergistic combination of an effective DNA delivery system and a target tissue that serves as a major immunological inductive site. Experimental gene gun-based nucleic acid vaccines can achieve potent humoral and cytotoxic cellular immune responses in rodent models following immunization with as little as 16 ng of DNA. Equally strong responses have also been elicited in larger animals, such as pigs and monkeys, following epidermal immunization with as little as 2 to 4 micrograms of DNA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8717384     DOI: 10.1016/0168-1656(96)80298-7

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  15 in total

Review 1.  Technologies for enhanced efficacy of DNA vaccines.

Authors:  Fadi Saade; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

2.  Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates.

Authors:  M J McCluskie; C L Brazolot Millan; R A Gramzinski; H L Robinson; J C Santoro; J T Fuller; G Widera; J R Haynes; R H Purcell; H L Davis
Journal:  Mol Med       Date:  1999-05       Impact factor: 6.354

3.  Measles virus DNA vaccination: antibody isotype is determined by the method of immunization and by the nature of both the antigen and the coimmunized antigen.

Authors:  A I Cardoso; N Sixt; A Vallier; J Fayolle; R Buckland; T F Wild
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

4.  Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.

Authors:  Joseph F Bower; Xinzhen Yang; Joseph Sodroski; Ted M Ross
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

5.  Infectivity-enhancing antibodies to Ebola virus glycoprotein.

Authors:  A Takada; S Watanabe; K Okazaki; H Kida; Y Kawaoka
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

6.  Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization.

Authors:  D R Surman; K R Irvine; E P Shulman; T M Allweis; S A Rosenberg; N P Restifo
Journal:  J Immunol Methods       Date:  1998-05-01       Impact factor: 2.303

Review 7.  Ultrasound mediated delivery of drugs and genes to solid tumors.

Authors:  Victor Frenkel
Journal:  Adv Drug Deliv Rev       Date:  2008-04-03       Impact factor: 15.470

8.  The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods.

Authors:  Shixia Wang; Chunghua Zhang; Lu Zhang; Jun Li; Zuhu Huang; Shan Lu
Journal:  Vaccine       Date:  2008-03-06       Impact factor: 3.641

9.  DNA Vaccines in Pigs: From Immunization to Antigen Identification.

Authors:  Francesc Accensi; Laia Bosch-Camós; Paula L Monteagudo; Fernando Rodríguez
Journal:  Methods Mol Biol       Date:  2022

10.  Coadministration of DNA encoding interleukin-6 and hemagglutinin confers protection from influenza virus challenge in mice.

Authors:  D L Larsen; N Dybdahl-Sissoko; M W McGregor; R Drape; V Neumann; W F Swain; D P Lunn; C W Olsen
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.